Immune checkpoint inhibitors (ICI), such as antibodies against programmed cell death-1, PD-L1, or cytotoxic T lymphocyte–associated protein-4, are an evolving treatment option for non–small cell lung cancer (NSCLC; refs. 1–4). The gene discussed is CD274; the disease is non-small cell lung carcinoma.